Strategic and operational support for a start-up oncology company Challenge A start-up company was planning to license an immunomodulatory product from a European pharmaceutical company. The therapy had been unsuccessfully tried in allergic disorders, but the client saw an opportunity to exploit the drug in an oncology setting, particularly in combination with immuno-oncology compounds such as the PD-1 and PD-L1 inhibitors. Owing to its unique mechanism of action, the drug could stimulate or suppress the immune system, depending on the biological context. The client company was in its infancy, and needed a Chief Medical Officer with substantial experience to lay the groundwork for the clinical side of the operation. Solution Bill Slichenmyer, an experienced oncology development consultant,

Join for free to read